Skip to content

Aura Biosciences, Inc. AURA Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Merck & Co. logo
Merck & Co.MRK
UroGen Pharma logo
UroGen PharmaURGN
CG Oncology logo
CG OncologyCGON
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
Nuvation Bio logo
Nuvation BioNUVB

Other financials

Income statement

See full
Operating income-$34.9M-20.1%
Net income-$33.7M-22.6%
EPS (diluted)-$0.50+9.1%

Balance sheet

See full
Cash & equivalents$84.8M+122%
Total debt$17.0M-7.9%
Total equity$107.2M-16.2%
Total assets$137.7M-11.4%

Cash flow

See full
Operating cash flow-$29.9M-28.0%
CapEx$102.0K-45.5%
Free cash flow-$30.0M-27.4%

Valuation

See full
Market cap$709.23M+89.4%
Enterprise value$641.43M+80.8%

Returns & leverage

See full
Return on equity-95.6%+222pp
Debt / equity0.2×0.0×
Current ratio7.1×-4.0×

Where this comes from

Reported directly by Aura Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aura Biosciences, Inc.'s deferred tax assets and other non-current assets?
Aura Biosciences, Inc. (AURA) reported deferred tax assets and other non-current assets of $517K in Q1 2026.
What is the long-term trend for Aura Biosciences, Inc.'s deferred tax assets and other non-current assets?
Over 3 years (2022 to 2025), Aura Biosciences, Inc.'s deferred tax assets and other non-current assets has grown at a 3.6% compound annual growth rate (CAGR), from $423K to $471K.